KLK2 Recombinant Rabbit mAb (SDT-4461-19)

Catalog Number: S0B2498 Application: WB, IHC-P Reactivity: Hu Conjugation: Unconjugated Brand: Starter

Price:

$100 USD

Size: 25μl 100μl 500μl 1ml

Quantity:

For shipping services or bulk orders, you may request a quotation.

Secure checkout with

View full details

Product Details

Product Specification

Host	Rabbit
Antigen	KLK2
Immunogen	Synthetic Peptide
Accession	P20151
Clone Number	SDT-4461-19
Antibody Type	Recombinant mAb
Isotype	IgG
Application	WB, IHC-P
Reactivity	Hu
Positive Sample	LNCaP
Purification	Protein A
Concentration	0.25 mg/ml
Conjugation	Unconjugated
Physical Appearance	Liquid
Storage Buffer	PBS, 40% Glycerol, 0.05% BSA, 0.02% sodium azide
Stability & Storage	12 months from date of receipt / reconstitution, -20 °C as supplied

Dilution

application	dilution	species
WB	1:500	Hu
IHC-P	1:2000	Hu

Background

KLK2, or human kallikrein-related peptidase 2, is a trypsin-like serine protease that is predominantly expressed by prostate tissue and secreted into semen. Physiologically, KLK2 activates and complements its homolog KLK3 (prostate-specific antigen, PSA), participating in the cleavage of semen coagulum proteins to facilitate semen liquefaction. At the pathological level, KLK2 plays a critical role in prostate cancer—it is a gene regulated by the androgen receptor (AR) signaling pathway, with its expression levels closely correlating with disease progression and significantly elevated in metastatic lesions. In recent years, due to its cell-surface expression on prostate cancer cells and its highly tissue-specific nature (normally expressed only in prostate tissue), KLK2 has emerged as a highly attractive therapeutic target. A variety of cutting-edge therapies targeting KLK2 have entered clinical trials, including bispecific T-cell engagers (such as Pasritamig/JNJ-78278343), chimeric antigen receptor T-cell (CAR-T) therapies, and radionuclide-conjugated antibody-drug conjugates, all aimed at providing more precise treatment options for patients with advanced prostate cancer.

Picture

Western Blot

WB result of KLK2 Recombinant Rabbit mAb
Primary antibody: KLK2 Recombinant Rabbit mAb at 1/500 dilution
Lane 1: DU 145 whole cell lysate 20 µg
Lane 2: LNCaP whole cell lysate 20 µg
Negative control: DU 145 whole cell lysate
Secondary antibody: Goat Anti-Rabbit IgG (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 29, 25 kDa
Observed MW: 29, 25 kDa
This blot was developed with high sensitivity substrate

Immunohistochemistry

IHC shows positive staining in paraffin-embedded human prostate. Anti-KLK2 antibody was used at 1/2000 dilution, followed by a HRP Polymer for Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.

IHC shows positive staining in paraffin-embedded human prostatic cancer (case 1). Anti-KLK2 antibody was used at 1/2000 dilution, followed by a HRP Polymer for Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.

IHC shows positive staining in paraffin-embedded human prostatic cancer (case 2). Anti-KLK2 antibody was used at 1/2000 dilution, followed by a HRP Polymer for Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.

Negative control: IHC shows negative staining in paraffin-embedded human liver. Anti-KLK2 antibody was used at 1/2000 dilution, followed by a HRP Polymer for Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.